HRAS and neoplasm: An important question is whether MAP2K1-driven tumours align with conventional WHO melanomagenesis pathways, alongside BRAF, NRAS, and NF1 mutations, or pathway IV (Spitz), alongside kinase gene fusions and HRAS mutations.